A new medication called sodium zirconium cyclosilicate did not prove equal to a potassium-restricted diet for treating high potassium in people with type 2 diabetes, according to Gram Research analysis of the SILVERSTAR trial. While 77.8% of people taking the medication reached normal potassium levels compared to 68.4% on the diet, this difference wasn’t statistically significant enough to prove the medication works as well as dietary changes.
Researchers tested whether a new medication called sodium zirconium cyclosilicate could work as well as a potassium-restricted diet for treating high potassium levels in people with type 2 diabetes. According to Gram Research analysis, the study involved 76 participants split into two groups: one taking the medication and one following a strict diet. While the medication group showed slightly better results, the study didn’t prove the drug was truly equal to the diet approach. The findings suggest both methods can help lower potassium, but the diet approach remains a solid first-line treatment option.
Key Statistics
In the SILVERSTAR randomized controlled trial of 76 adults with type 2 diabetes, sodium zirconium cyclosilicate achieved normal potassium levels in 77.8% of participants compared to 68.4% in the potassium-restricted diet group, but failed to demonstrate noninferiority.
A 2026 study published in the Journal of Diabetes Investigation found that the medication group had mean serum potassium levels 0.23 mEq/L lower than the diet group at week 4-6, suggesting a modest advantage for the drug approach.
The potassium-restricted diet group experienced decreased dietary fiber intake during the SILVERSTAR trial, indicating difficulty maintaining strict dietary restrictions over the 4-6 week study period.
The Quick Take
- What they studied: Can a new medication (sodium zirconium cyclosilicate) work as well as eating less potassium to treat dangerously high potassium levels in people with type 2 diabetes?
- Who participated: 76 adults with type 2 diabetes and high potassium levels were randomly assigned to either take the medication (37 people) or follow a potassium-restricted diet (39 people) for 4-6 weeks.
- Key finding: The medication group had 77.8% of people reach normal potassium levels compared to 68.4% in the diet group, but this difference wasn’t large enough to prove the medication was truly equal to the diet.
- What it means for you: If you have high potassium from diabetes, dietary changes remain a reliable first-line treatment. The medication may help in some cases, but more research is needed before it can replace diet as the standard approach.
The Research Details
This was a randomized controlled trial, which is one of the strongest types of medical research. Researchers divided 76 people with type 2 diabetes and high potassium into two groups: one group took sodium zirconium cyclosilicate (a medication that helps remove potassium from the body), while the other group followed a strict diet limiting potassium intake. Both groups were followed for 4-6 weeks, and researchers measured their potassium levels at the end to see which approach worked better.
The study was ‘open-label,’ meaning both the participants and researchers knew who was taking the medication versus following the diet. This is less ideal than a ‘blinded’ study where people don’t know which treatment they’re getting, but it’s often necessary for diet studies. The researchers used a statistical method called ’noninferiority testing,’ which asks whether the new medication works at least as well as the diet approach, not whether it works better.
This research design matters because high potassium (hyperkalemia) is a serious problem for people with diabetes, especially those taking certain blood pressure or kidney medications. Finding an easier treatment than strict dietary restriction could help more people manage this condition. However, the noninferiority design means the study was specifically looking to see if the medication could match the diet’s effectiveness, not beat it.
The study had several strengths: it was randomized (reducing bias), included multiple medical centers, and carefully measured potassium levels. However, the sample size was relatively small (76 people), which makes it harder to detect true differences. The study was open-label, which could introduce bias. One serious concern: one participant in the medication group died suddenly during the study, though the cause wasn’t clearly linked to the treatment. The study also failed to meet its primary goal in the main analysis, though a secondary analysis suggested the medication might work better.
What the Results Show
The main finding was that the medication group did not prove to be noninferior to the diet group. In the primary analysis, 77.8% of people taking the medication reached normal potassium levels (3.5-5.0 mEq/L) compared to 68.4% in the diet group—a difference of about 9.4 percentage points. However, this difference was too small and uncertain to prove the medication was truly equal to the diet approach.
When researchers looked at average potassium levels at the end of the study, the medication group had slightly lower potassium (0.23 mEq/L lower), which was statistically significant. This suggests the medication may have a small advantage in lowering potassium. However, in a secondary analysis of only the people who fully completed the study as planned, the medication did appear noninferior to the diet (83.9% versus 70.8% reaching normal levels), but this finding is considered exploratory and less reliable than the primary analysis.
Quality of life scores didn’t change between groups, meaning neither treatment made people feel significantly better or worse. However, people in the diet group had lower dietary fiber intake by the end of the study, suggesting they may have struggled to maintain the strict diet. The medication was generally well-tolerated with few side effects, though one participant in the medication group experienced a sudden death during the study. The cause of this death wasn’t definitively established as related to the medication, but it raises a safety concern that warrants further investigation.
This study adds important information to existing research on potassium management in diabetes. Previous studies have shown that potassium-restricted diets work but are difficult for many people to follow long-term. Sodium zirconium cyclosilicate is a newer medication that has shown promise in other patient populations. This trial is one of the first to directly compare the medication to dietary restriction in diabetic patients. The results suggest the medication may be helpful but doesn’t clearly outperform the established dietary approach.
The study had several important limitations. First, the sample size was relatively small (76 people), making it harder to detect true differences between treatments. Second, the study was open-label, so both participants and researchers knew who was getting the medication versus the diet, which could introduce bias. Third, the study only lasted 4-6 weeks, which is relatively short for evaluating long-term management. Fourth, one participant died suddenly in the medication group, raising safety questions that couldn’t be fully resolved in this small study. Finally, the study failed to meet its primary statistical goal, which weakens confidence in the medication’s effectiveness compared to diet.
The Bottom Line
For people with type 2 diabetes and high potassium levels, a potassium-restricted diet remains the recommended first-line treatment based on this research. The medication (sodium zirconium cyclosilicate) may be considered as an additional option or for people who cannot follow a strict diet, but it hasn’t been proven superior to dietary changes. Anyone considering this medication should discuss it with their doctor, especially given the single death reported in the study. Confidence level: Moderate for diet effectiveness; Lower for medication as a replacement therapy.
This research matters most for people with type 2 diabetes who have high potassium levels, particularly those taking ACE inhibitors, ARBs, or potassium-sparing diuretics. It’s also relevant for doctors managing diabetic patients with kidney disease. People without diabetes or those with normal potassium levels don’t need to worry about these findings. Those with severe kidney disease should consult their nephrologist before making changes.
If following a potassium-restricted diet, most people should see improvements in potassium levels within 2-4 weeks, as shown in this study. If taking the medication, similar timelines apply. However, long-term management (months to years) requires consistent adherence to whichever approach is chosen.
Frequently Asked Questions
Is sodium zirconium cyclosilicate better than diet for lowering potassium in diabetes?
The SILVERSTAR trial found the medication didn’t prove superior to a potassium-restricted diet. While 77.8% on medication versus 68.4% on diet reached normal potassium levels, this difference wasn’t statistically significant enough to confirm the medication works as well as diet.
How long does it take to lower potassium with diet or medication?
Both approaches showed results within 4-6 weeks in this study. Most people achieved normal potassium levels (3.5-5.0 mEq/L) within this timeframe, though individual results vary based on starting potassium levels and adherence.
Can I stop eating low-potassium foods if I take this medication?
The study suggests dietary restriction remains the primary treatment approach. The medication may help supplement diet but shouldn’t replace it entirely. Always consult your doctor before changing your potassium management strategy.
What are the side effects of sodium zirconium cyclosilicate?
The medication was generally well-tolerated with few reported side effects in this trial. However, one participant died suddenly, though causation wasn’t definitively established. More research is needed to fully understand long-term safety.
Who should consider this medication instead of diet?
People with type 2 diabetes who struggle to follow strict potassium-restricted diets might discuss this medication with their doctor. However, diet remains the first-line treatment based on current evidence. Individual circumstances should guide treatment decisions.
Want to Apply This Research?
- Track daily potassium intake in grams and log weekly potassium blood test results (in mEq/L) to monitor whether dietary changes or medication are working effectively.
- Set daily reminders to avoid high-potassium foods (bananas, oranges, potatoes, spinach, tomatoes) and log meals to stay within a 2,000-3,000 mg daily potassium target, adjusting based on doctor’s recommendations.
- Create a weekly chart comparing potassium levels over time, set alerts for upcoming blood tests, and track adherence to dietary restrictions or medication doses to identify patterns affecting potassium control.
This article summarizes research findings and should not replace professional medical advice. High potassium is a serious medical condition requiring doctor supervision. Do not change your diet, medications, or potassium management without consulting your healthcare provider. The SILVERSTAR trial did not demonstrate that sodium zirconium cyclosilicate is noninferior to dietary restriction, and one participant experienced a sudden death during the medication group. Anyone considering this medication should discuss potential risks and benefits with their physician. This information is for educational purposes only and is not a substitute for personalized medical care.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.